Why The Cardlytics (CDLX) Story Is Resetting After Guidance, Exits And Analyst Target Cuts

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Cardlytics is back in focus after analysts reset price targets closer to the US$1 to US$1.25 range, with a fair value estimate holding near US$1.04. These changes sit alongside commentary that Q4 results, Q1 guidance, the BofA exit, and the Bridg divestiture now leave the "bar appropriately level set," with some calling the shares firmly in "show me" territory. As you read on, you will see how to track this evolving analyst narrative and what it can mean for your own view on the stock.

Stay updated as the Fair Value for Cardlytics shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Cardlytics.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Lake Street views Q1 guidance as a reset that brings expectations in line with the near term effects of the BofA exit and Bridg divestiture. It sees this as putting the performance "bar" at a more realistic level. With expectations reset, Lake Street frames Cardlytics as a "show me" story. This implies that if execution matches the new guidance range, there may be room for investors to reassess the current valuation anchors around US$1 to US$1.25.

🐻 Bearish Takeaways

Lake Street cut its price target to US$1.25 from US$1.50 and keeps a Hold rating, signaling caution on near term execution after Q1 guidance and recent business changes. Evercore ISI reduced its price target to US$1 from US$2 and maintains an In Line rating following the Q4 report and Q1 guidance. This points to a more constrained view on upside until the business impact of recent moves is clearer.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NasdaqGM:CDLX 1-Year Stock Price Chart

We've flagged 4 risks for Cardlytics. See which could impact your investment.

What's in the News

Cardlytics plans to ask shareholders at the May 20, 2026 Annual Meeting to approve a reverse stock split in a range of 1-for-5 to 1-for-15, along with a proportional reduction in authorized common shares. The final reverse split ratio would be determined by the Board of Directors without the need for an additional shareholder vote. The company states that the main goal of the proposed reverse split is to increase the per share market price of its common stock in order to meet Nasdaq Global Market minimum bid price requirements. For Q1 2026, Cardlytics issued revenue guidance of US$35.0m to US$40.0m, providing a current range for investors to compare with upcoming results.

Story Continues

How This Changes the Fair Value For Cardlytics

Fair value estimate remains at about US$1.04, with the updated figure at US$1.0375. Forecast revenue change stays around a 13.01% decline, with only a very small numerical refinement. Net profit margin moves from 9.93% to 10.09% in the updated model. Future P/E adjusts from 6.07x to 5.98x in the latest assumptions. Discount rate stays at 12.33% with no change to the required rate of return used.

Never Miss an Update: Follow The Narrative

Narratives connect a company's business story, its key drivers, and its risks to the assumptions behind forecasts and fair value. They refresh as new data, guidance, and events come through, so your view stays grounded in the latest information.

Head over to the Simply Wall St Community and follow the Narrative on Cardlytics to stay up to date on:

How new financial institution partners, non bank publishers, and Cardlytics Rewards are broadening user reach and supporting operating leverage. The role of first party purchase data, AI driven analytics, and self serve tools in keeping advertisers engaged and spending on the platform. Key risks around bank partner content restrictions, pricing pressure, advertiser churn, slower product investment, and reliance on debt funding.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CDLX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments